Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
20
days
Creating a smoother path to scientific publication
AuthorsThomas Lemberger; Kevin M. Ryan
Affiliations1. EMBO Heidelberg Germany; 2. FEBS Press Cambridge UK; 3. Cancer Research UK Scotland Institute Glasgow UK; 4. School of Cancer Sciences University of Glasgow Glasgow UK
68
days
Interpreting the effects of DNA polymerase variants at the structural level
AuthorsMatteo Arnaudi; Karolina Krzesińska; Ludovica Beltrame; Pablo Sánchez‐Izquierdo Besora; Matteo Tiberti; Mef Nilbert; Anna Rohlin; Elena Papaleo
Affiliations1. Cancer Structural Biology Danish Cancer Institute Copenhagen Denmark; 2. Cancer Systems Biology, Section for Bioinformatics, Department of Health and Technology Technical University of Denmark Lyngby Denmark; 3. Institute of Clinical Medicine, Dept. Oncology and Pathology Lund University Sweden; 4. Department of Clinical Research Copenhagen University Hospital Amager and Hvidovre Denmark; 5. Department of Clinical Genetics and Genomics Sahlgrenska University Hospital Gothenburg Sweden; 6. Department of Laboratory Medicine Institute for Biomedicine, Sahlgrenska Academy, University of Gothenburg Sweden
162
days
ESR1 methylation and ESR1 mutations in circulating tumor cells ( CTCs ) and paired plasma‐ cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study
AuthorsDimitra Stergiopoulou; Athina Markou; Eleonora Nicolo; Mara S Serafini; Qiang Zhang; Youbin Zhang; Lorenzo Gerratana; Andrew A. Davis; Huiping Liu; William J Gradishar; Carolina Reduzzi; Massimo Cristofanilli; Evi Lianidou
Affiliations1. Analysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry University of Athens Athens Greece; 2. Division of Hematology and Medical Oncology Weill Cornell Medicine/New York‐Presbyterian Hospital New York NY USA; 3. Robert H. Lurie Cancer Center of Northwestern University Feinberg School of Medicine Chicago IL USA; 4. Department of Medical Oncology Centro di Riferimento Oncologico di Aviano (CRO), IRCCS Aviano Italy; 5. Division of Oncology Washington University St. Louis MO USA
233
days
Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil
AuthorsRadhika Sain; Yann Le Page; Frédéric Percevault; Emmanuelle Becker; Luc Negroni; Almudena Fernandez; Marta Cantero; Diego Muñoz‐Santos; Lluís Montoliu; Cyrille Garnier; Michael Primig
Affiliations1. Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) ‐ UMR_S 1085 Univ Rennes Rennes France; 2. ESBS, ‐BCS‐UMR7242 Illkirch France; 3. National Centre of Biotechnology (CNB‐CSIC) Madrid Spain; 4. Biomedical Research Networking Center on Rare Diseases (CIBERER‐ISCIII) Madrid Spain; 5. Department of Medicine. Faculty of Medicine, Health and Sports Universidad Europea de Madrid Madrid Spain
132
days
DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients
AuthorsChao Chen; Jiancheng Cheng; Ruili Hou; Xiaoyuan Zheng; Li Su; Maria Moksnes Bjaanæs; Anna Karlsson; Maria Planck; Johan Staaf; Åslaug Helland; Manel Esteller; David C. Christiani; Feng Chen; Xiaofei Cao; Ruyang Zhang
Affiliations1. Department of Biostatistics, Center for Global Health, School of Public Health Nanjing Medical University Jiangsu China; 2. Information Center, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University Jiangsu China; 3. Department of Environmental Health Harvard T.H. Chan School of Public Health Boston MA USA; 4. Department of Cancer Genetics Institute for Cancer Research, Oslo University Hospital Norway; 5. Division of Oncology, Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research Lund University Sweden; 6. Institute of Clinical Medicine University of Oslo Norway; 7. Cancer Epigenetics Group Josep Carreras Leukaemia Research Institute (IJC) Barcelona Spain; 8. Centro de Investigación Biomédica en Red Cancer (CIBERONC) Madrid Spain; 9. Institució Catalana de Recerca i Estudis Avançats (ICREA) Barcelona Spain; 10. Physiological Sciences Department, School of Medicine and Health Sciences University of Barcelona Spain; 11. Pulmonary and Critical Care Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School Boston USA; 12. China International Cooperation Center for Environment and Human Health Nanjing Medical University Jiangsu China; 13. Department of Anesthesiology and Perioperative Medicine, The First School of Clinical Medicine The First Affiliated Hospital of Nanjing Medical University Jiangsu China; 14. Changzhou Medical Center Nanjing Medical University Changzhou Jiangsu China; 15. Laboratory for Digital Intelligence & Health Governance Nanjing Medical University Jiangsu China
121
days
EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas
AuthorsDonovan Pineau; Leonor Garcia; Hugo Arnold; Antonija Hanžek; Maialen Arrieta; Laurent R Gauthier; Christine Granotier‐Beckers; François D Boussin; Amaury Herbet; Marie Hautière; Valentin Asei‐Ceschino; Clémentin Jacques; Laura Brard; Thomas Harnois; Valérie Coronas; Bruno Constantin; Aurélien Chatelier; Jean Chemin; Serge Urbach; Martial Seveno; Szimonetta Hideg; Chantal Ripoll; Kasandra Aguilar‐Cázarez; Min Zheng; Guo‐Hao Huang; Sheng‐Qing Lv; Lei Zhang; Philippe Rondard; Laurent Prezeau; Jean‐Philippe Pin; Hugues Duffau; Luc Bauchet; Valérie Rigau; Franck Denat; Charles Truillet; Didier Boquet; Jean‐Philippe Hugnot
Affiliations1. Institut de Génomique Fonctionnelle Université de Montpellier, CNRS, INSERM France; 2. University of Bordeaux, CNRS, IBGC UMR5095 France; 3. Université Paris Cité and Université Paris‐Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations Fontenay‐aux‐Roses France; 4. Université Paris‐Saclay, CEA, DMTS, SPI France; 5. Institut Génétique Humaine Université de Montpellier, CNRS, INSERM France; 6. 4CS, Laboratory Channels and Connexins in Cancers and Cell Stemness, UR 22751 University of Poitiers France; 7. PReTI Laboratory, UR 24184 University of Poitiers France; 8. BioCampus Montpellier Université de Montpellier, CNRS, INSERM France; 9. Jinfeng Laboratory Chongqing China; 10. Neurosurgery Department Montpellier University Medical Center France; 11. Pathology Department Montpellier University Medical Center France; 12. Université Bourgogne, Europe, CNRS, UMR 6302 Dijon France; 13. Université Paris‐Saclay, CEA, CNRS, Inserm, BioMaps, Orsay France
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days